Zepbound: The Most Effective FDA-Approved Weight Loss Medication

Zepbound contains tirzepatide, a dual GIP and GLP-1 receptor agonist that activates both incretin pathways to produce substantial appetite suppression, delayed gastric emptying, and improved metabolic signaling. The dual mechanism targets complementary pathways in the gut, pancreas, and brain to reduce caloric intake and promote sustained weight loss that exceeds what GLP-1-only medications achieve.

Zepbound (tirzepatide) was approved by the FDA in November 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Manufactured by Eli Lilly, it is the first dual GIP/GLP-1 receptor agonist approved specifically for weight loss. Zepbound produced the largest average weight loss of any FDA-approved anti-obesity medication in clinical trials, with participants in the SURMOUNT-1 trial losing up to 22.5% of body weight at the highest dose. This places it in a class by itself for non-surgical weight management.

The SURMOUNT clinical trial program demonstrated unprecedented weight loss for a pharmaceutical intervention. SURMOUNT-1 was the flagship trial, enrolling 2,539 adults with obesity without diabetes. At the 15 mg dose, mean weight loss was 22.5% (approximately 52 lbs from a mean starting weight of 231 lbs). Over one-third of the 15 mg group lost 25% or more of their body weight, outcomes that rival Roux-en-Y gastric bypass surgery. SURMOUNT-3 explored a sequential approach: after a 12-week intensive lifestyle intervention produced initial weight loss, adding tirzepatide amplified total weight reduction to approximately 26% from the original baseline. SURMOUNT-4 demonstrated the consequences of discontinuation, with patients who stopped tirzepatide regaining most of their lost weight over 52 weeks.

While no head-to-head trial has directly compared Zepbound (tirzepatide) and Wegovy (semaglutide) at their full weight-management doses, cross-trial comparisons and the head-to-head SURPASS-2 diabetes data consistently favor tirzepatide for greater weight loss. SURMOUNT-1 showed 22.5% weight loss with tirzepatide 15 mg vs 14.9% in STEP 1 with semaglutide 2.4 mg. However, these were different trials with different populations, so direct comparison has limitations. Both medications have similar gastrointestinal side effect profiles. The choice between them often depends on insurance coverage, prescriber preference, medication availability, and individual patient response.

Zepbound is administered via a single-dose, pre-filled auto-injector pen once weekly. The titration schedule starts at 2.5 mg and increases every 4 weeks through six dose levels up to 15 mg. The maintenance dose is individualized; patients may be maintained at 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg based on tolerability and weight-loss response. Higher doses generally produce more weight loss, but some patients achieve excellent results at intermediate doses. Injections are given subcutaneously in the abdomen, thigh, or upper arm. The injection site should be rotated weekly.

Zepbound has a list price of approximately $1,059 per month. Insurance coverage for weight management is evolving: many commercial plans have added Zepbound to their formularies, but coverage is not universal. Prior authorization is typically required, including documentation of BMI and comorbidities. Eli Lilly offers a savings program for commercially insured patients that can reduce out-of-pocket costs. Medicare Part D does not currently cover anti-obesity medications. Eli Lilly has also introduced Zepbound direct-to-consumer vial options at a lower price point, making the medication accessible to patients who may not have insurance coverage.